The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Platelet membrane glycoprotein IIb/IIIa inhibitors, a new class of potent antiplatelet agents, have been used in the treatment of acute coronary syndromes as well as in the prevention of complications after percutaneous coronary interventions. Approximately 50,000 patients with coronary artery disease have been enrolled in randomized studies of glycoprotein IIb/IIIa inhibitors. The purpose of this article is to review the pharmacology of glycoprotein IIb/IIIa inhibitors, the results of the clinical trials using these agents, and their current use in percutaneous coronary interventions and the treatment of acute coronary syndromes.
Sabatine
M S
MS
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Jang
I K
IK
D000077284:Abciximab; D000085:Acetates / Q000627:therapeutic use; D000208:Acute Disease; D000284:Administration, Oral; D000409:Alanine / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001550:Benzamidines / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy* / Q000628:therapy; D000077542:Eptifibatide; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy; D010091:Oximes / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011759:Pyrrolidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015607:Stents; D013577:Syndrome; D013921:Thrombocytopenia / Q000139:chemically induced; D015912:Thrombolytic Therapy; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000085:Acetates; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D001550:Benzamidines; D007140:Immunoglobulin Fab Fragments; D010091:Oximes; D010455:Peptides; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011759:Pyrrolidines; D014443:Tyrosine; C084062:lamifiban; C120234:orbofiban; D000077466:Tirofiban; D000077542:Eptifibatide; D000409:Alanine; C091295:xemilofiban; D000077284:Abciximab; C100917:sibrafiban